Published in Vestn Oftalmol on January 01, 1983
Novel functional activities of anti-DNA autoantibodies from sera of patients with lymphoproliferative and autoimmune diseases. Appl Biochem Biotechnol (1998) 0.96
Anti-DNA autoantibodies reveal toxicity to tumor cell lines. Immunol Lett (2002) 0.85
Sequence specificity of isolated DNA-adenine methylases from Mycobacterium smegmatis (butyricum) and Shigella sonnei 47 cells. Biochem Int (1985) 0.83
Sequence specificity of isolated DNA-cytosine methylases from Shigella sonnei 47 cells. Biochem Int (1984) 0.80
Substrate specificity of catalytic autoantibodies in neurodegenerative processes. Dokl Biochem Biophys (2007) 0.80
[Site-specificity of DNA methylases from Shigella sonnei 47 cells]. Biokhimiia (1985) 0.80
[Catalytic autoantibodies--a new molecular instrument in cardiology and ophthalmology]. Ter Arkh (2006) 0.78
[Immunogenetic HLA markers of chronic viral hepatitis]. Ter Arkh (2005) 0.77
[Diagnostic and pathogenetic implications of the site specificity of antibody proteases in multiple sclerosis]. Vestn Ross Akad Med Nauk (2010) 0.76
Natural antibody catalytic activities in mice with autoimmune disorders. Dokl Biochem (2001) 0.76
[Cytokines and their role in pathogenesis of diabetic retinopathy]. Vestn Oftalmol (2011) 0.76
[The current concept of immunological disorders in the case of basal-cell carcinoma]. Arkh Patol (2009) 0.76
[Aproaches to immunotherapy in different immunophenotypes of cutaneous basal cell carcinoma]. Vopr Onkol (2012) 0.76
β1 integrin as the integrating component in cell-cell cooperation for maintenance of lens transparency. Dokl Biochem Biophys (2014) 0.76
[DNA-abzymes in rheumatoid arthritis: pathogenetic and clinical significance]. Ter Arkh (2005) 0.76
[Changes in the T-lymphocyte subpopulations in patients with severe eye burns]. Oftalmol Zh (1990) 0.76
[Isoelectric focusing of DNA-methylases from Shigella sonnei 47]. Vopr Med Khim (1983) 0.75
Caspase-dependent cytotoxicity of anti-DNA autoantibodies. Dokl Biochem Biophys (2001) 0.75
[Post-infection clinico-immunologic syndrome: fundamentals of etiopathogenesis and immunogenodiagnostic strategy]. Vestn Ross Akad Med Nauk (2009) 0.75
Catalytic autoantibodies in multiple sclerosis: pathogenetic and clinical aspects. Bull Exp Biol Med (2005) 0.75
[Introduction into PPPM: experience of the past and tomorrow's reality]. Vestn Ross Akad Med Nauk (2013) 0.75
[Syndrome of secondary immunodeficiency: pathogenesis and approaches to treatment]. Klin Med (Mosk) (2002) 0.75
[Glial tumors of the brain: current aspects of their classification and bases for genetic predisposition]. Arkh Patol (2009) 0.75
[Modern programs of treatment and rehabilitation of patients with basaliomas: their pathogenic substantiation and clinical effectiveness]. Vestn Ross Akad Med Nauk (2005) 0.75
[Immunogenodiagnosis and postinfection immunodeficiency syndrome in a hospital doctor's practice (a review of literature)]. Klin Lab Diagn (2006) 0.75
[Spectral domain optical coherence tomography for evaluation of transpupillary thermotherapy efficacy in early uveal melanoma]. Vestn Oftalmol (2013) 0.75
[Tumor necrosis factor alpha and interferon alpha in patients with myocarditis.]. Kardiologiia (2004) 0.75
[Clinico-immunological parallels in patients with focal scleroderma]. Vestn Dermatol Venerol (1989) 0.75
[EHF-therapy of herpetic keratouveitis]. Vopr Kurortol Fizioter Lech Fiz Kult (2002) 0.75
[Antibody-mediated proteolysis of myelin-associated proteins as a new mechanism of control over demyelinization processes in multiple sclerosis]. Vestn Ross Akad Med Nauk (2007) 0.75
[Fractionation and purification of DNA-methylases from Shigella sonnei 47]. Biokhimiia (1985) 0.75
[Catalytic autoantibodies and their future in practical medicine]. Ter Arkh (2002) 0.75
[Current protease-antibody-based serodiagnostic tools and their use in the diagnosis of autoimmune thyroid diseases]. Klin Lab Diagn (2010) 0.75
[Postinfection autoimmune syndrome: pathogenetic features and modern protocols of clinical immunogenodiagnosis]. Ter Arkh (2007) 0.75
Isoelectric focusing of bacterial DNA methylases. Biochem Int (1983) 0.75
[The immunophysiological and immunopathological aspects of scleroderma systematica: fundamental and clinical aspects]. Patol Fiziol Eksp Ter (2007) 0.75
[Two cases of bilateral uveal melanoma]. Vestn Oftalmol (2011) 0.75
[Introduction to medical abzymology: the present and the prospect]. Vestn Ross Akad Med Nauk (2005) 0.75
[Study of the conditions of activation and stabilization of DNA-methylases from Shigella sonnei 47 during fractionation, purification and storage]. Biokhimiia (1986) 0.75
[Pathogenetic and symptomatic treatment of endocrine ophthalmopathies]. Vestn Oftalmol (1984) 0.75
[Tissue-specific retinal proteins in vertebrate evolution]. Zh Evol Biokhim Fiziol (1981) 0.75
[Comprehensive examination of the female urogenital tract infection by polymerase chain reaction using multiplex test systems]. Klin Lab Diagn (2010) 0.75
[Possible role of natural cytotoxicity in impairment of collagen catabolism in focal scleroderma]. Vopr Med Khim (1988) 0.75
[Autoimmune myocarditis: current aspects of immune pathogenesis]. Vestn Ross Akad Med Nauk (2002) 0.75
[Fluorescence angiography in the diagnosis of pigment-free melanomas of the choroid]. Vestn Oftalmol (2005) 0.75
[Differential diagnosis of early central choroidal melanoma and late stage age-related macula degeneration]. Vestn Oftalmol (2013) 0.75
[Achievements and prospects of clinical abzymology]. Vestn Ross Akad Med Nauk (2005) 0.75
[Glial tumors of the brain: classification, present-day aspects of immunopathogenesis and immunogenetic diagnostics]. Vestn Ross Akad Med Nauk (2005) 0.75
[Metastatic choroidal carcinoma. Two clinical cases]. Vestn Oftalmol (2013) 0.75
[The connection between the decomposition of mature collagen and the level of natural cytotoxicity in patients with focal scleroderma]. Vopr Med Khim (1991) 0.75
[Post-infectious clinical-immunological syndrome and its place in clinical practice]. Ter Arkh (2009) 0.75
[Immunocorrecting therapy in focal scleroderma]. Vestn Dermatol Venerol (1987) 0.75
[Classification and clinical characteristics of endocrine ophthalmopathy]. Vestn Oftalmol (1983) 0.75
[Modern approaches to treating and preventing autoimmune myocarditis]. Vestn Ross Akad Med Nauk (2003) 0.75
[Current pathogenetic model of rheumatoid arthritis and its role in clinical practice]. Ter Arkh (2004) 0.75
[Autoimmunity and autoimmune syndrome: norm and pathology]. Vestn Ross Akad Med Nauk (2010) 0.75
[Antibodies as a molecular-diagnostic tool in serodiagnostics and seroprognostication of autoimmune myocarditis (literature review)]. Klin Lab Diagn (2005) 0.75
[A risk of metastasis of choroid melanoma after brachytherapy]. Vestn Oftalmol (2003) 0.75
[A clinico-immunological assessment of the efficacy of combined methods of treating patients with different immunopathological forms of focal scleroderma]. Vestn Dermatol Venerol (1990) 0.75
[DNA-abzymes and their clinical significance in systemic lupus erythematosis]. Ter Arkh (2001) 0.75
[Cytokines as a diagnostic and therapeutic tool in patients with myocarditis]. Vestn Ross Akad Med Nauk (2005) 0.75
[Catalytic autoantibodies as a new molecular instrument in rheumatological practice]. Ter Arkh (2006) 0.75
[The use of fermented milk drink with topinambur for the treatment of Helicobacter infection in the liquidators of Chernobyl nuclear power plant accident]. Vopr Pitan (2003) 0.75
On the catalytic activity of autoantibodies in multiple sclerosis. Dokl Biochem Biophys (2004) 0.75
[Immunological aspects of laboratory diagnosis of chronic urticaria]. Klin Lab Diagn (2001) 0.75
[Antithyroid antibodies of varying specificity in the pathogenesis and diagnosis of autoimmune thyroid diseases]. Ter Arkh (2009) 0.75
[Chronic pyelonephritis: immunopathogenesis and clinicodiagnostic value of its specific features]. Ter Arkh (2007) 0.75
["Functionality" of antibodies: clinical implications]. Ter Arkh (2008) 0.75
[Glial tumors of the brain: current aspects of the immunopathogenesis and immunogenodiagnosis]. Arkh Patol (2007) 0.75
[Autoantibodies of various levels of specificity and function in pathogenesis and diagnosis of autoimmune thyroid diseases]. Ter Arkh (2008) 0.75
Factors of activation and stabilization of DNA-methylases from Shigella sonnei 47 and Mycobacterium smegmatis butyricum cells. Biochem Int (1987) 0.75
[Proteomics as a fundamental tool for subclinical screening, tests verification and assessment of applied therapy]. Vestn Ross Akad Med Nauk (2013) 0.75
[Architectonics of cell subpopulations of peripheral blood in patients with autoimmune myocarditis: clinical and pathogenetic aspects]. Ter Arkh (2008) 0.75
[The cyclic nucleotide system of patients with focal scleroderma]. Vestn Dermatol Venerol (1990) 0.75
[Introduction to preventive and predictive medicine: past experience and future reality]. Ter Arkh (2012) 0.75